Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Submits Plan to Regain NYSE Compliance

NEW YORK (GenomeWeb News) – Interleukin Genetics said today that it has submitted a plan to the New York Stock Exchange's Alternext market for regaining compliance with the exchange's continued listing requirements.

The Waltham, Mass.-based firm announced at the end of December that it had received a letter for the Alternext saying that it was not in compliance with certain listing criteria. Specifically, the firm's stockholders' equity is less than $6 million and it has reported losses from continuing operations and net losses in its five most recent fiscal years.

Interleukin said that it expects the exchange to formally respond to its plan within 45 days. If the plan is expected, Interleukin would continue to float on the exchange up to June 23, 2010, and would be subject to periodic review. If the plan is not accepted, it would have the right to appeal the decision.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.